Literature DB >> 15525997

Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress.

Matthew N Hill1, Sachin Patel, Erica J Carrier, David J Rademacher, Brandi K Ormerod, Cecilia J Hillard, Boris B Gorzalka.   

Abstract

Deficits in cognitive functioning and flexibility are seen following both chronic stress and modulation of endogenous cannabinoid (eCB) signaling. Here, we investigated whether alterations in eCB signaling might contribute to the cognitive impairments induced by chronic stress. Chronic stress impaired reversal learning and induced perseveratory behavior in the Morris water maze without significant effect on task acquisition. These cognitive impairments were reversed by exogenous cannabinoid administration, suggesting deficient eCB signaling underlies these phenomena. In line with this hypothesis, chronic stress downregulated CB1 receptor expression and significantly reduced the content of the endocannabinoid 2-arachidonylglycerol within the hippocampus. CB1 receptor density and 2-arachidonylglycerol content were unaffected in the limbic forebrain. These data suggest that stress-induced downregulation of hippocampal eCB signaling contributes to problems in behavioral flexibility and could play a role in the development of perseveratory and ruminatory behaviors in stress-related neuropsychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15525997     DOI: 10.1038/sj.npp.1300601

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  121 in total

1.  Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.

Authors:  N P Bowles; M N Hill; S M Bhagat; I N Karatsoreos; C J Hillard; B S McEwen
Journal:  Neuroscience       Date:  2011-09-10       Impact factor: 3.590

Review 2.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

4.  Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.

Authors:  Matthew N Hill; Larissa M Froese; Anna C Morrish; Jane C Sun; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

5.  Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.

Authors:  Francis Rodriguez Bambico; Noam Katz; Guy Debonnel; Gabriella Gobbi
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 6.  Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.

Authors:  Regina A Mangieri; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

7.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 8.  Adaptations of striatal endocannabinoid system during stress.

Authors:  Silvia Rossi; Valentina De Chiara; Alessandra Musella; Giorgia Mataluni; Lucia Sacchetti; Giorgio Bernardi; Alessandro Usiello; Diego Centonze
Journal:  Mol Neurobiol       Date:  2009-03-07       Impact factor: 5.590

9.  Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Authors:  Richard L Suplita; Sarah A Eisenstein; Mark H Neely; Anna M Moise; Andrea G Hohmann
Journal:  Neuropharmacology       Date:  2007-07-19       Impact factor: 5.250

Review 10.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.